{
    "2021-03-09": [
        [
            {
                "time": "2021-09-15",
                "original_text": "Novartis' (NVS) NSCLC Drug Fails to Meet Primary Endpoint",
                "features": {
                    "keywords": [
                        "Novartis",
                        "NSCLC",
                        "Drug",
                        "Fails",
                        "Primary",
                        "Endpoint"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-09-16",
                "original_text": "Novartis Canakinumab Fails To Improve Survival In Late-Stage Lung Cancer Trial",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Canakinumab",
                        "Fails",
                        "Survival",
                        "Late-Stage",
                        "Lung",
                        "Cancer",
                        "Trial"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-09-17",
                "original_text": "The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data",
                "features": {
                    "keywords": [
                        "Regulatory",
                        "Setback",
                        "Acadia",
                        "Lilly",
                        "Diabetes",
                        "Antibody",
                        "Treatment",
                        "Collaboration",
                        "Aytu",
                        "Positive",
                        "COVID-19",
                        "Data"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-09-18",
                "original_text": "Molecular Partners/Novartis's COVID-19 Antiviral Therapy Shows Encouraging Action Early-Stage Study",
                "features": {
                    "keywords": [
                        "Molecular",
                        "Partners",
                        "Novartis",
                        "COVID-19",
                        "Antiviral",
                        "Therapy",
                        "Encouraging",
                        "Action",
                        "Early-Stage",
                        "Study"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-09-19",
                "original_text": "Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Phase",
                        "III",
                        "canakinumab",
                        "ACZ885",
                        "second",
                        "third-line",
                        "treatment",
                        "chemotherapy",
                        "non-small",
                        "cell",
                        "lung",
                        "cancer"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}